Accessibility Menu
Idt Australia logo

Idt Australia(ASX) IDT

Market CapA$19.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-40%
5 Year-92%
1 Year-28%
1 Month+2%
A$0.05
+6.52%
+0.00Today
Idt Australia last closing stock price
MetricPriceDate
Last closeAUD 0.052026-09-07
Idt Australia stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.08%AUD 0.052026-08-31
1 month+2.08%AUD 0.052026-08-07
3 month+32.43%AUD 0.042026-06-09
Year to date-3.92%AUD 0.052025-12-30
1 year-27.94%AUD 0.072025-09-05
3 year-16.95%AUD 0.062023-09-08
5 year-91.69%AUD 0.592021-09-08
Since inception-39.69%AUD 0.081992-01-02

Idt Australia Financials at a Glance

Market Cap

A$19.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$40.12M

Net Income (TTM)

-A$10.78M

EPS (TTM)

-A$0.01

P/E Ratio

-7.19

Dividend

A$0.00

Beta (Volatility)

0.21 (Low)

Price

A$0.05

Volume

25,560

Open

A$0.05

Previous Close

A$0.05

Daily Range

A$0.05 - A$0.05

52-Week Range

A$0.03 - A$0.07

Estimated Earnings Date

Feb 23, 2027

IDT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Idt Australia

IDT Australia Limited is a pharmaceutical company engaged in the complete lifecycle of drug development, from research and manufacturing to global distribution. The company specializes in both active pharmaceutical ingredients (APIs) and finished dosage forms, offering a range of services including analytical support and contract manufacturing.

Products and Services
  • Manufacturing of active pharmaceutical ingredients (APIs)
  • Comprehensive analytical support and quality control services
  • Medicinal cannabis products and contract manufacturing solutions
Growth Outlook
  • Recent quarterly revenue reached AUD 10.63 million, showing a positive trend
  • Strong demand for contract manufacturing services is expected to drive growth
  • Expansion into medicinal cannabis market presents new revenue opportunities
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 36.5 million
  • Current ratio of 2.33 indicates strong liquidity position
  • Net income for the latest quarter was AUD -1.4 million, reflecting ongoing challenges
IDT Australia Limited operates in the healthcare sector, specifically within the drug manufacturing industry. The company has established a solid foundation since its inception in 1975, with a focus on innovation and quality. The recent quarterly revenue indicates a recovery trajectory, while the current ratio suggests a robust ability to meet short-term obligations. Despite facing challenges reflected in the net income figures, the company is well-positioned to capitalize on growth opportunities, particularly in the expanding medicinal cannabis market. Investors may find IDT Australia Limited an intriguing option within the pharmaceutical sector, given its comprehensive service offerings and potential for future growth.
AI Generated • Aug 24, 2026

Industry

Pharmaceuticals

CEO

Mark Anthony Simari

Headquarters

Boronia, VIC 3155, AU

IDT Financials

Key Financial Metrics (TTM)

Gross Margin

21.10%

Operating Margin

-8.09%

Net Income Margin

-13.35%

Return on Equity

-13.81%

Return on Capital

-5.51%

Return on Assets

-7.79%

Earnings Yield

-13.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$19.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

426.89M

Volume

25.56K

Avg. Volume

276.27K

Financials (TTM)

Gross Profit

A$13.99M

Operating Income

-A$7.96M

EBITDA

-A$7.28M

Operating Cash Flow

-A$5.18M

Capital Expenditure

-A$2.61M

Free Cash Flow

-A$7.80M

Cash & ST Invst.

A$2.52M

Total Debt

A$10.83M

Idt Australia Performance Analysis

Idt Australia annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 6,935,000-42.7%
20242024-06-30AUD 13,226,00090.7%
20252025-06-30AUD 19,217,00045.3%
20262026-06-30AUD 20,357,0005.9%
Idt Australia sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3126.5%
Q42025-06-30-11.5%
Q22025-12-314.8%
Q42026-06-309.4%
Idt Australia annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.03621.3%
20242024-06-30AUD -0.02-54.3%
20252025-06-30AUD -0.0221.9%
20262026-06-30AUD -0.01-64.6%
Idt Australia sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-72.7%
Q42025-06-30-48.7%
Q22025-12-3172.6%
Q42026-06-30-6.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$10.63M

+28.3%

Gross Profit

A$1.96M

-61.4%

Gross Margin

18.45%

N/A

Market Cap

A$19.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$125.88K

N/A

Employees

156

N/A

Net Income

-A$1.40M

+9.9%

EBITDA

-A$300.00K

+80.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$2.52M

+178.2%

Total Debt

A$10.83M

+142.3%

Accounts Receivable

A$6.17M

-6.1%

Inventory

A$2.63M

+56.4%

Long Term Debt

A$10.09M

N/A

Short Term Debt

A$738.00K

-83.5%

Return on Assets

-7.79%

N/A

Return on Invested Capital

-5.61%

N/A

Free Cash Flow

-A$919.00K

+84.3%

Operating Cash Flow

-A$569.00K

+89.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NOX.AXNoxopharm Limited
A$0.07-6.58%
AGH.AXAlthea Group Holdings Limited
A$0.02-4.76%
AT1.AXAtomo Diagnostics Limited
A$0.02-5.26%
IMC.AXImmuron Limited
A$0.05+35.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About IDT

What is the current price of Idt Australia?

Idt Australia is trading at A$0.05 per share.

What is the 52-week range for Idt Australia?

Over the past 52 weeks, Idt Australia has traded between A$0.03 and A$0.07.

How much debt does Idt Australia have?

As of the most recent reporting period, Idt Australia reported total debt of A$10.83M.

How much cash does Idt Australia have on hand?

Idt Australia reported A$2.52M in cash and cash equivalents in its most recent financial results.

What is Idt Australia’s dividend yield?

Idt Australia does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.